Trials / Completed
CompletedNCT01206361
Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
Persistence Of Use Of Topical Prostaglandin Fixed Dose Combination In The United Kingdom Primary Care: An Observational Study In Thin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,015 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XALACOM | Xalacom eye drops |
| DRUG | Duotrav | Duotrav eye drops |
| DRUG | Ganfort | Ganfort eye drops |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-09-21
- Last updated
- 2021-02-02
Source: ClinicalTrials.gov record NCT01206361. Inclusion in this directory is not an endorsement.